Thomas BOUCHER

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 14/12/2020
• Auteurs : Jeffrey ChilcoteQuinn KonopackyRobert de RosaRandall HamperBruce MacintoshChristian MaroisMarshall D. PerrinDmitry SavranskyRémi SoummerJean-Pierre VéranGuido AgapitoArlene AlemanMark AmmonsMarco BonagliaMarc-Andre BoucherMaeve CurlissJennifer DunnSimone EspositoGuillaume FilionJoeleff FitzsimmonsIsabel KainDan KerleyJean-Thomas LandryOlivier LardiereMarie Lemoine-BusserolleDuan LiMary Anne LimbachAlex MadurowiczJérôme MaireMamadou N'DiayeEric NielsenLisa PoyneerLaurent PueyoKaitlyn SummeyColeman Thomas
• Organismes : Joseph Louis LAGRANGE Centre National de la Recherche Scientifique Observatoire de la Côte d'Azur

---

Fichiers liés : GPI_2_0_SPIE_2020 (21).pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/12/2020
• Auteurs : Jane MunckeAnna-Maria AnderssonThomas BackhausJustin M BoucherBethanie Carney AlmrothArturo Castillo CastilloJonathan ChevrierBarbara A. DemeneixJorge A EmmanuelJean Baptiste FiniDavid GeeBirgit GeuekeKsenia J. GrohJerrold J HeindelJane HoulihanChristopher D KassotisCarol F KwiatkowskiLisa y LeffertsMaricel V MaffiniOlwenn MartinJohn Peterson MyersAngel NadalCristina NerinKatherine E PelchSeth Rojello FernandezRoger M SargisAna SotoLeonardo TrasandeLaura N VandenbergMartin WagnerChangqing WuR. Thomas ZoellerMartin Scheringer
• Organismes : Physiologie moléculaire et adaptation Physiologie moléculaire et adaptation Tufts University School of Medicine [Boston] La République des savoirs : Lettres, Sciences, Philosophie
• Publié dans Environmental Health le 28/10/2020

---

Résumé : Food packaging is of high societal value because it conserves and protects food, makes food transportable and conveys information to consumers. It is also relevant for marketing, which is of economic significance. Other types of food contact articles, such as storage containers, processing equipment and filling lines, are also important for food production and food supply. Food contact articles are made up of one or multiple different food contact materials and consist of food contact chemicals. However, food contact chemicals transfer from all types of food contact materials and articles into food and, consequently, are taken up by humans. Here we highlight topics of concern based on scientific findings showing that food contact materials and articles are a relevant exposure pathway for known hazardous substances as well as for a plethora of toxicologically uncharacterized chemicals, both intentionally and non-intentionally added. We describe areas of certainty, like the fact that chemicals migrate from food contact articles into food, and uncertainty, for example unidentified chemicals migrating into food. Current safety assessment of food contact chemicals is ineffective at protecting human health. In addition, society is striving for waste reduction with a focus on food packaging. As a result, solutions are being developed toward reuse, recycling or alternative (non-plastic) materials. However, the critical aspect of chemical safety is often ignored. Developing solutions for improving the safety of food contact chemicals and for tackling the circular economy must include current scientific knowledge. This cannot be done in isolation but must include all relevant experts and stakeholders. Therefore, we provide an overview of areas of concern and related activities that will improve the safety of food contact articles and support a circular economy. Our aim is to initiate a broader discussion involving scientists with relevant expertise but not currently working on food contact materials, and decision makers and influencers addressing single-use food packaging due to environmental concerns. Ultimately, we aim to support science-based decision making in the interest of improving public health. Notably, reducing exposure to hazardous food contact chemicals contributes to the prevention of associated chronic diseases in the human population.

---

Fichiers liés : 12940_2020_Article_572.pdf

---

Source

---

• Type de publi. : Ouvrage (y compris édition critique et traduction)
• Date de publi. : 04/11/2020
• Auteurs : Philippe SaléSandrine BartholomeThomas BoucherJacky DespriéeFrancesca Di NapoliMonique Dondin-PayreAlexandre FontaineLaurent FournierAlix FourréSylvia Jouanneau-BigotVictorine MataouchekSébastien MilletCéline VillenaveBéatrice Marsollier
• Organismes : Institut national de recherches archéologiques préventives Cités, Territoires, Environnement et Sociétés [Tours] Institut national de recherches archéologiques préventives Ecomusée du Véron Institut national de recherches archéologiques préventives Cités, Territoires, Environnement et Sociétés [Tours] Centre National de la Recherche Scientifique Anthropologie et Histoire des Mondes Antiques Institut national de recherches archéologiques préventives Institut national de recherches archéologiques préventives Institut national de recherches archéologiques préventives Institut national de recherches archéologiques préventives Institut national de recherches archéologiques préventives Cités, Territoires, Environnement et Sociétés [Tours] Institut national de recherches archéologiques préventives Institut national de recherches archéologiques préventives Institut national de recherches archéologiques préventives

---

Résumé : De l’oppidum gaulois au village actuel, l’histoire de Saint-Marcel (Argentomagus), dans l’Indre, est riche et complexe. Le site archéologique a fait l’objet de nombreuses interventions archéologiques programmées ou préventives, en particulier sur le plateau des Mersans, où s’étendent l’occupation gauloise et une partie de l’agglomération secondaire antique, notamment le sanctuaire. Les secteurs périphériques sont moins bien connus. Du nord-ouest au nord-est des Mersans, les grandes voies interurbaines du plateau dominant la Creuse traversent le secteur des Courates pour relier l’agglomération. Différentes mentions y font état de vestiges, mais leur organisation et leur nature demeurent méconnues. Dans ce contexte et préalablement à la construction d’une maison individuelle, une opération de diagnostic a été réalisée en 2013 par R. De Filippo (Inrap), rue des Courattes, sur la parcelle cadastrée AV 200. Après prescription du service régional de l’Archéologie du Centre-Val-de-Loire, une fouille préventive a été menée par l’Inrap sur l’ensemble de la surface de la parcelle, soit 1 700 m².

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/11/2020
• Auteurs : Axel UrsenbachVincent MaxMarine MaurelFirouzé Bani-SadrAmandine Gagneux-BrunonRodolphe GarraffoIsabelle RavauxOlivier RobineauAlain MakinsonDavid ReyC Drobacheff-ThiébautA FoltzerKevin BouillerL Hustache-MathieuCatherine ChirouzeQ LepillerF BozonO BabreA BrunelP MuretH LaurichesseO LesensM VidalN MrozekAumeran C.O BaudV CorbinP Letertre-GibertS CasanovaJ ProuteauC JacometI LamauryI FabreE CurlierR OuissaC Herrmann-StorckB TressieresT BonijolyM ReceveurF BoulardC DanielC ClavelD MerrienP PerréT GuimardO BollangierS LeautezM MorrierL LaineF AderA BeckerF BironA BoibieuxL CotteT FerryP MiailhesT PerpointStéphane RouxC Triffault-FillitS DegroodtC BrochierF ValourC ChidiacA MénardA BelkhirP ColsonC DhiverA MadridM Martin-DegiovaniL MeddebM MokhtariA MotteA RaouxC TamaletC ToméiHervé Tissot-DupontS BrégigeonO Zaegel-FaucherV Obry-RoguetH LarocheM OrticoniM SoaviP Geneau de LamarlièreE RessiotM DucassouI JaquetS GalieA GalinierP MartinetM LandonA RitlengA IvanovaC DebreuxC LionsI Poizot-MartinS AbelO CabrasL CuzinK GuitteaudM IlliaquerS Pierre-FrançoisL OseiJ PasquierK RomeE SidaniJ TurmelC VaracheA CabiéN AtouiM BistoquetE DelaporteV Le MoingN MeftahC Merle de BoeverB Montesa Montoya FerrerE TuaillonJ ReynesM AndréL BoyerM BouillonM DelestanC RabaudT MayB HoenC AllavenaC BernaudE BillaudC BironB BonnetS BouchezD BoutoilleC Brunet-CartierC DeschanvresN HallP MorineauV ReliquetS SécherM CavellecA SoriaV FerréE André-GarnierA RodallecM LefebvreO GrossiO AubryF RaffiP PuglieseS BreaudC CeppiD ChirioE CuaP DellamonicaE DemonchyA de MonteJ DurantC EtienneS FerrandoC MichelangeliV MondainA NaqviN OranI PerbostS PilletC PradierB Prouvost-KellerK RissoV RioP RogerE RosenthalS SausseI TouitouS Wehrlen-PuglieseG ZouzouL HocquelouxT PrazuckC GubavuA SèveA MakaC BoulardG ThomasA CheretC GoujardY QuertainmontE TeicherN LerolleO DeradjiA Barrail-TranR LandmanV JolyJ GhosnC RiouxS LarivenA GervaisF LescureS MatheronF LouniZ JuliaC Mackoumbou-NkoukaS Le GacC CharpentierD DescampsG PeytavinY YazdanpanahK AmazzoughV Avettand-FenoëlG BenabdelmoumenP BossiG CessotC CharlierP ConsignyF DanionA DureaultC DuvivierJ GoeschR GueryB HenryK JidarF LanternierP LoubetO LortholaryC LouisinJ LourencoP ParizeB PilmisF TouamM ValantinR TubianaR AgherSophie SeangL SchneiderR PalichC BlancC KatlamaJ BergerY N’guyenD LambertI KmiecM HentzienA BrunetV BrodardFirouzé Bani-SadrP TattevinM RevestF SoualaM BaldeyrouS Patrat-DelonJ ChapplainF BenezitMaeva DupontM PoinotA MaillardC PronierFlorian LemaitreC GuennounM Poisson-VanierT JovelinJ SinteffC ArvieuxElisabeth Botelho-NeversA FrésardV RonatF LuchtP FischerM PartisaniC CheneauM PriesterM BatardC Bernard-HenryE de MautortSamira Fafi-KremerM AlvarezN BiezunskiA DebardCyrille DelpierreP LansalotL LelièvreG Martin-BlondelM PiffautL PorteK SaunePierre DelobelF AjanaE AïssiI AlcarazV BacletL BocketA BoucherP ChoisyT HuleuxB Lafon-DesmursA MeybeckM PradierN VigetM Valette
• Organismes : Hôpitaux Universitaires de Strasbourg Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320 Hôpital universitaire Robert Debré [Reims] Hôpital universitaire Robert Debré [Reims] CHU Nice [Cimiez] Institut Hospitalier Universitaire Méditerranée Infection Centre Hospitalier de Tourcoing Département Maladies Infectieuses et Tropicales [CHRU Montpellier] Hôpitaux Universitaires de Strasbourg Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Régional Universitaire [Montpellier] Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes Centre Hospitalier Régional Universitaire [Montpellier] Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes Centre Hospitalier Régional Universitaire [Montpellier] Pathogénèse et contrôle des infections chroniques (PCCI) Centre Hospitalier Régional Universitaire [Montpellier] Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] Hôpital universitaire Robert Debré [Reims] Infections Cardiovasculaires Virales et inflammation en pathologie humaine (CardioVir) UMR-S 1320
• Publié dans Journal of Antimicrobial Chemotherapy le 31/10/2020

---

Résumé : Background: Integrase strand transfer inhibitors (INSTIs) are increasingly used in patients living with HIV due to their safety, effectiveness and high genetic barrier. However, an association with weight gain has recently been suggested and several cases of diabetes mellitus have been reported with raltegravir and dolutegravir. The long-time metabolic impact of these recent molecules remains unclear. Objectives: To assess if an INSTI as a third agent is statistically associated with new-onset diabetes mellitus compared with an NNRTI or a PI. Patients and methods: Patients undergoing first-line combined ART (cART) without diabetes at baseline were retrospectively included from the Dat’AIDS French cohort study (ClinicalTrials.gov NCT02898987). Incident diabetes mellitus was defined as a notification of new diabetes in the medical history, a glycated haemoglobin (HbA1c) level superior to 7.5% or the start of a diabetes therapy following the initiation of ART. Results: From 2009 to 2017, 19 462 patients were included, among which 265 cases of diabetes mellitus occurred. Multivariate and survival analyses did not highlight an increase in new-onset diabetes in patients undergoing cART with an INSTI as a third agent compared with an NNRTI or a PI. BMI >30 kg/m2, age >37 years old (in survival analysis), black race or Hispanic ethnicity, arterial hypertension and AIDS were associated with a higher proportion of incident diabetes. Conclusions: INSTIs were not statistically associated with new-onset diabetes. However, clinicians should remain aware of this possible metabolic comorbidity, particularly in patients with a high BMI and older patients.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/09/2020
• Auteurs : Charles EbersoleMaya MathurErica BaranskiDiane-Jo Bart-PlangeNicholas ButtrickChristopher R ChartierKatherine CorkerMartin CorleyJoshua HartshorneHans IjzermanLjiljana LazarevićHugh RabagliatiIvan RopovikBalazs AczelLena AeschbachLuca AndrighettoJack ArnalHolly ArrowPeter BabincakBence BakosGabriel BaníkErnest BaskinRadomir BelopavlovićMichael BernsteinMichał BiałekNicholas BloxsomBojana BodrožaDiane BonfiglioLeanne BoucherFlorian BrühlmannClaudia BrumbaughErica CasiniYiling ChenCarlo ChiorriWilliam ChopikOliver ChristAntonia CiunciHeather ClaypoolSean CoaryMarija ČolićW. Matthew CollinsPaul CurranChris DayBenjamin DeringAnna DreberJohn EdlundFilipe FalcãoAnna FedorLily FeinbergIan FergusonMáire FordMichael FrankEmily FrybergerAlexander GarintherKatarzyna GawrylukKayla AshbaughMauro GiacomantonioSteffen GiessnerJon GraheRosanna GuadagnoEwa HałasaPeter HancockRias HilliardJoachim HüffmeierSean HughesKatarzyna IdzikowskaMichael InzlichtAlan JernWilliam Jiménez-LealMagnus JohannessonJennifer Joy-GabaMathias KauffDanielle KellierGrecia KessingerMallory KidwellAmanda KimbroughJosiah KingVanessa KolbSabina KołodziejMarton KovacsKarolina KrasuskaSue KrausLacy KruegerKatarzyna KuchnoCaio Ambrosio LageEleanor LangfordCarmel LevitanTiago Jessé Souza de LimaHause LinSamuel LinsJia LoyDylan ManfrediŁukasz MarkiewiczMadhavi MenonBrett MercierMitchell MetzgerVenus MeyetAilsa MillenJeremy MillerAndres MontealegreDon MooreRafał MudaGideon NaveAustin Lee NicholsSarah NovakChristian NunnallyAna OrlićAnna PalinkasAngelo PannoKimberly ParksIvana PedovićEmilian PękalaMatthew PennerSebastiaan PessersBoban PetrovićThomas PfeifferDamian PieńkoszEmanuele PretiDanka PurićTiago RamosJonathan RavidTimothy RazzaKatrin RentzschJuliette RichetinSean RifeAnna Dalla RosaKaylis Hase RudyJanos SalamonBlair SaundersPrzemysław SawickiKathleen SchmidtKurt SchuepferThomas SchultzeStefan Schulz-HardtAstrid SchützAni ShabazianRachel ShubellaAdam SiegelRúben SilvaBarbara SiomaLauren SkorbLuana Elayne Cunha de SouzaSara SteegenL. SteinR. Weylin SternglanzDarko StojilovićDaniel StorageGavin Brent SullivanBarnabas SzasziPeter SzecsiOrsolya SzökeAttila SzutsManuela ThomaeNatasha TidwellCarly ToccoAnn-Kathrin TorkaFrancis TuerlinckxWolf VanpaemelLeigh Ann VaughnMichelangelo VianelloDomenico ViganolaMaria VlachouRyan WalkerSophia WeissgerberAaron WichmanBradford WigginsDaniel WolfMichael WoodDavid ZealleyIris ŽeželjMark ZrubkaBrian Nosek
• Organismes : Laboratoire Inter-universitaire de Psychologie : Personnalité, Cognition, Changement Social
• Publié dans Advances in Methods and Practices in Psychological Science le 26/10/2020

---

Résumé : Replication studies in psychological science sometimes fail to reproduce prior findings. If these studies use methods that are unfaithful to the original study or ineffective in eliciting the phenomenon of interest, then a failure to replicate may be a failure of the protocol rather than a challenge to the original finding. Formal pre-data-collection peer review by experts may address shortcomings and increase replicability rates. We selected 10 replication studies from the Reproducibility Project: Psychology (RP:P; Open Science Collaboration, 2015) for which the original authors had expressed concerns about the replication designs before data collection; only one of these studies had yielded a statistically significant effect ( p < .05). Commenters suggested that lack of adherence to expert review and low-powered tests were the reasons that most of these RP:P studies failed to replicate the original effects. We revised the replication protocols and received formal peer review prior to conducting new replication studies. We administered the RP:P and revised protocols in multiple laboratories (median number of laboratories per original study = 6.5, range = 3–9; median total sample = 1,279.5, range = 276–3,512) for high-powered tests of each original finding with both protocols. Overall, following the preregistered analysis plan, we found that the revised protocols produced effect sizes similar to those of the RP:P protocols (Δ r = .002 or .014, depending on analytic approach). The median effect size for the revised protocols ( r = .05) was similar to that of the RP:P protocols ( r = .04) and the original RP:P replications ( r = .11), and smaller than that of the original studies ( r = .37). Analysis of the cumulative evidence across the original studies and the corresponding three replication attempts provided very precise estimates of the 10 tested effects and indicated that their effect sizes (median r = .07, range = .00–.15) were 78% smaller, on average, than the original effect sizes (median r = .37, range = .19–.50).

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/07/2020
• Auteurs : Adrien Le GuillouPascal PuglieseFrançois RaffiAndré CabieLise CuzinChristine KatlamaClotilde AllavenaMoustapha DraméLaurent CotteFirouzé Bani-SadrM OrticoniM SoaviI Luquet- BessonE RessiotM Carta- PadovaniM DucassouH BertoneS GalieA GalinierM MonclarA RitlengA IvanovaC Blanco-BetancourtC LionsI Poizot-MartinC DhiverM Saadia MokhtariA MénardH Tissot DupontC ToméiL MeddebA BelkhirI RavauxM AlvarezN BiezunskiA DebardCyrille DelpierreP LansalotL LelièvreG Martin-BlondelM PiffautL PorteK SauneP DelobelP PuglieseS BreaudC CeppiD ChirioE CuaP DellamonicaE DemonchyA de MonteJ DurantC EtienneS FerrandoR GarraffoC MichelangeliV MondainC AllavenaC BernaudE BillaudC BironB BonnetS BouchezD BoutoilleC Brunet-CartierC DeschanvresB GaboritN HallT JovelinP Le TurnierP MorineauV ReliquetS SécherM CavellecA SoriaV FerréE André-GarnierA RodallecM LefebvreO GrossiO AubryF RaffiK AmazzoughG BenabdelmoumenP BossiG CessotC CharlierP ConsignyF DanionA DureaultC DuvivierJ GoeschR GueryB HenryK JidarF LanternierP LoubetO LortholaryC LouisinJ LourencoP ParizeB PilmisF TouamM ValantinR TubianaR AgherSophie SeangL SchneiderR PalichC BlancC KatlamaA CabiéL CuzinS AbelS Pierre-FrançoisJ PasquierK GuitteaudJ TurmelM IlliaquerP FischerM PartisaniC CheneauM PriesterM BatardC Bernard-HenryE de MautortSamira Fafi-KremerDominique ReyCatherine ChirouzeQ GardiennetF Bani-SadrJ BergerY N’guyenD LambertM HentzienD LebrunA BrunetI KmiecV BrodardL CotteC ChidiacT FerryF AderF BironA BoibieuxP MiailhesT PerpointI SchliengerJ LippmannE BraunJ KoffiC LonguetV GuéripelC Augustin-NormandC BrochierS DegroodtN AtouiV Le MoingA MakinsonN MeftahC Merle de BoeverB MontesA Montoya FerrerJ ReynesM AndréL BoyerM BouillonM DelestanT MayL HocquelouxT PrazuckC GubavuA SèveA MakaC BoulardG ThomasA CheretC GoujardY QuertainmontE TeicherN LerolleO DeradjiA Barrail-TranR LandmanV JolyC RiouxS LarivenA GervaisF LescureS MatheronF LouniC GodardZ JuliaM ChansombatD RahliC Mackoumbou-NkoukaC CharpentierD DescampsG PeytavinY YazdanpanahP TattevinM RevestF SoualaM BaldeyrouS Patrat-DelonJ ChapplainF BenezitMaeva DupontM PoinotA MaillardC PronierFlorian LemaitreC GuennounM Poisson-VanierT JovelinJ SinteffC ArvieuxElisabeth Botelho-NeversA Gagneux-BrunonA FrésardF LuchtF AjanaE AïssiI AlcarazV BacletL BocketA BoucherP ChoisyT HuleuxB Lafon-DesmursA MeybeckM PradierO RobineauN VigetM ValetteB HoenI LamauryI FabreE CurlierR OuissaK SchepersC Herrmann-StorckN DournonD MerrienP PerréT GuimardO BollangierS LeautezM Morrier
• Organismes : Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Universitaire de Nice Centre d’Investigation Clinique de Nantes Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Service de maladies infectieuses et tropicales [Nantes] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Hospices Civils de Lyon Centre de Recherche en Cancérologie de Lyon Hôpital universitaire Robert Debré [Reims] Clinique Pasteur [Toulouse] Neurobiologie, plasticité tissulaire et métabolisme énergétique Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp]
• Publié dans Clinical Infectious Diseases le 30/10/2020

---

Résumé : Background: In late 2013, France was one of the first countries to recommend initiation of combination antiretroviral therapy (cART) irrespective of CD4 cell count. Methods: To assess the impact of achieving the second and third Joint United Nations Programme on HIV/AIDS 90-90-90 targets (ie, 90% of diagnosed people on sustained cART, and, of those, 90% virologically controlled) on human immunodeficiency virus (HIV) incidence, we conducted a longitudinal study to describe the epidemiology of primary HIV infection (PHI) and/or recent HIV infection (patients with CD4 cell count ≥500/mm3 at HIV diagnosis; (PRHI) between 2007 and 2017 in a large French multicenter cohort. To identify changes in trends in PHI and PRHI, we used single breakpoint linear segmented regression analysis. Results: During the study period, 61 822 patients were followed in the Dat'AIDS cohort; 2027 (10.0%) had PHI and 7314 (36.1%) had PRHI. The second and third targets were reached in 2014 and 2013, respectively. The median delay between HIV diagnosis and cART initiation decreased from 9.07 (interquartile range [IQR], 1.39-33.47) months in 2007 to 0.77 (IQR, 0.37-1.60) months in 2017. A decrease in PHI (-35.1%) and PRHI (-25.4%) was observed starting in 2013. The breakpoints for PHI and PRHI were 2012.6 (95% confidence interval [CI], 2010.8-2014.4) and 2013.1 (95% CI, 2011.3-2014.8), respectively. Conclusions: Our findings show that the achievements of 2 public health targets in France and the early initiation of cART were accompanied by a reduction of about one-third in PHI and PRHI between 2013 and 2017. Clinical trials registration: NCT02898987.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 11/07/2020
• Auteurs : Adrien Le GuillouPascal PuglieseFrançois RaffiAndré CabieLise CuzinChristine KatlamaClotilde AllavenaMoustapha DraméLaurent CotteFirouzé Bani-SadrM OrticoniM SoaviI Luquet- BessonE RessiotM Carta- PadovaniM DucassouH BertoneS GalieA GalinierM MonclarA RitlengA IvanovaC Blanco-BetancourtC LionsI Poizot-MartinC DhiverM Saadia MokhtariA MénardH Tissot DupontC ToméiL MeddebA BelkhirI RavauxM AlvarezN BiezunskiA DebardCyrille DelpierreP LansalotL LelièvreG Martin-BlondelM PiffautL PorteK SauneP DelobelP PuglieseS BreaudC CeppiD ChirioE CuaP DellamonicaE DemonchyA de MonteJ DurantC EtienneS FerrandoR GarraffoC MichelangeliV MondainC AllavenaC BernaudE BillaudC BironB BonnetS BouchezD BoutoilleC Brunet-CartierC DeschanvresB GaboritN HallT JovelinP Le TurnierP MorineauV ReliquetS SécherM CavellecA SoriaV FerréE André-GarnierA RodallecM LefebvreO GrossiO AubryF RaffiK AmazzoughG BenabdelmoumenP BossiG CessotC CharlierP ConsignyF DanionA DureaultC DuvivierJ GoeschR GueryB HenryK JidarF LanternierP LoubetO LortholaryC LouisinJ LourencoP ParizeB PilmisF TouamM ValantinR TubianaR AgherSophie SeangL SchneiderR PalichC BlancC KatlamaA CabiéL CuzinS AbelS Pierre-FrançoisJ PasquierK GuitteaudJ TurmelM IlliaquerP FischerM PartisaniC CheneauM PriesterM BatardC Bernard-HenryE de MautortSamira Fafi-KremerDominique ReyCatherine ChirouzeQ GardiennetF Bani-SadrJ BergerY N’guyenD LambertM HentzienD LebrunA BrunetI KmiecV BrodardL CotteC ChidiacT FerryF AderF BironA BoibieuxP MiailhesT PerpointI SchliengerJ LippmannE BraunJ KoffiC LonguetV GuéripelC Augustin-NormandC BrochierS DegroodtN AtouiV Le MoingA MakinsonN MeftahC Merle de BoeverB MontesA Montoya FerrerJ ReynesM AndréL BoyerM BouillonM DelestanT MayL HocquelouxT PrazuckC GubavuA SèveA MakaC BoulardG ThomasA CheretC GoujardY QuertainmontE TeicherN LerolleO DeradjiA Barrail-TranR LandmanV JolyC RiouxS LarivenA GervaisF LescureS MatheronF LouniC GodardZ JuliaM ChansombatD RahliC Mackoumbou-NkoukaC CharpentierD DescampsG PeytavinY YazdanpanahP TattevinM RevestF SoualaM BaldeyrouS Patrat-DelonJ ChapplainF BenezitMaeva DupontM PoinotA MaillardC PronierFlorian LemaitreC GuennounM Poisson-VanierT JovelinJ SinteffC ArvieuxElisabeth Botelho-NeversA Gagneux-BrunonA FrésardF LuchtF AjanaE AïssiI AlcarazV BacletL BocketA BoucherP ChoisyT HuleuxB Lafon-DesmursA MeybeckM PradierO RobineauN VigetM ValetteB HoenI LamauryI FabreE CurlierR OuissaK SchepersC Herrmann-StorckN DournonD MerrienP PerréT GuimardO BollangierS LeautezM Morrier
• Organismes : Hôpital universitaire Robert Debré [Reims] Centre Hospitalier Universitaire de Nice Centre d’Investigation Clinique de Nantes Service de maladies infectieuses et tropicales [Nantes] Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Service de maladies infectieuses et tropicales [Nantes] Centre d’Investigation Clinique de Nantes Épidémiologie Clinique et Vieillissement [UR5_2] Hôpital universitaire Robert Debré [Reims] Hospices Civils de Lyon Centre de Recherche en Cancérologie de Lyon Hôpital universitaire Robert Debré [Reims] Clinique Pasteur [Toulouse] Neurobiologie, plasticité tissulaire et métabolisme énergétique Stratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp]
• Publié dans Clinical Infectious Diseases le 30/10/2020

---

Résumé : Background: In late 2013, France was one of the first countries to recommend initiation of combination antiretroviral therapy (cART) irrespective of CD4 cell count. Methods: To assess the impact of achieving the second and third Joint United Nations Programme on HIV/AIDS 90-90-90 targets (ie, 90% of diagnosed people on sustained cART, and, of those, 90% virologically controlled) on human immunodeficiency virus (HIV) incidence, we conducted a longitudinal study to describe the epidemiology of primary HIV infection (PHI) and/or recent HIV infection (patients with CD4 cell count ≥500/mm3 at HIV diagnosis; (PRHI) between 2007 and 2017 in a large French multicenter cohort. To identify changes in trends in PHI and PRHI, we used single breakpoint linear segmented regression analysis. Results: During the study period, 61 822 patients were followed in the Dat'AIDS cohort; 2027 (10.0%) had PHI and 7314 (36.1%) had PRHI. The second and third targets were reached in 2014 and 2013, respectively. The median delay between HIV diagnosis and cART initiation decreased from 9.07 (interquartile range [IQR], 1.39-33.47) months in 2007 to 0.77 (IQR, 0.37-1.60) months in 2017. A decrease in PHI (-35.1%) and PRHI (-25.4%) was observed starting in 2013. The breakpoints for PHI and PRHI were 2012.6 (95% confidence interval [CI], 2010.8-2014.4) and 2013.1 (95% CI, 2011.3-2014.8), respectively. Conclusions: Our findings show that the achievements of 2 public health targets in France and the early initiation of cART were accompanied by a reduction of about one-third in PHI and PRHI between 2013 and 2017. Clinical trials registration: NCT02898987.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 09/06/2020
• Auteurs : Carla MavianSergei Kosakovsky PondSimone MariniBrittany Rife MagalisAnne-Mieke VandammeSimon DellicourSamuel V. ScarpinoCharlotte HouldcroftChristian Julián Villabona-ArenasTaylor K. PaisieNídia S. TrovãoChristina BoucherYun ZhangRichard H. ScheuermannOlivier GascuelTommy Tsan-Yuk LamMarc A. SuchardAna AbecasisEduan WilkinsonTulio de OliveiraAna I. BentoHeiko A. SchmidtDarren MartinJames HadfieldNuno FariaNathan D. GrubaughRichard A. NeherFélix Suárez ReyesPhilippe LemeyTanja StadlerJan AlbertKeith A. CrandallThomas LeitnerAlexandros StamatakisMattia ProsperiMarco Salemi
• Organismes : University of Florida [Gainesville] Temple University [Philadelphia] University of Florida [Gainesville] University of Florida [Gainesville] Catholic University of Leuven = Katholieke Universiteit Leuven Universidade Nova de Lisboa = NOVA University Lisbon Catholic University of Leuven = Katholieke Universiteit Leuven Université libre de Bruxelles Northeastern University [Boston] University of Cambridge [UK] London School of Hygiene and Tropical Medicine University of Florida [Gainesville] Fogarty International Center University of Florida [Gainesville] J. Craig Venter Institute [La Jolla, USA] J. Craig Venter Institute [La Jolla, USA] University of California [San Diego] Bioinformatique évolutive - Evolutionary Bioinformatics The University of Hong Kong David Geffen School of Medicine [Los Angeles] Universidade Nova de Lisboa = NOVA University Lisbon University of KwaZulu-Natal [Durban, Afrique du Sud] University of KwaZulu-Natal [Durban, Afrique du Sud] Indiana University [Bloomington] Universität Wien = University of Vienna University of Cape Town Fred Hutchinson Cancer Research Center [Seattle] University of Oxford Yale School of Public Health Biozentrum [Basel, Suisse] Catholic University of Leuven = Katholieke Universiteit Leuven Catholic University of Leuven = Katholieke Universiteit Leuven Department of Biosystems Science and Engineering [ETH Zürich] Karolinska Institutet [Stockholm] Milken Institute School of Public Health Los Alamos National Laboratory Heidelberg Institute for Theoretical Studies Karlsruhe Institute of Technology = Karlsruher Institut für Technologie University of Florida [Gainesville] University of Florida [Gainesville]
• Publié dans Proceedings of the National Academy of Sciences of the United States of America le 31/10/2020

---

Fichiers liés : 12522.full.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 20/05/2020
• Auteurs : Jose Carlos BenitezMarie Eve BoucherEric DansinMallorie KerjouanJulien MazieresEric PichonFrancois ThillaysPierre-Emmanuel FalcozBenoit RochYoussef OulkhouirCalcagno FabienLuc ThibervilleChristelle Clément DucheneFranck MorinPascale MissyPascal Alexandre ThomasJean-Michel MauryThierry MolinaNicolas GirardBenjamin Besse
• Organismes : Institut Gustave Roussy Institut Gustave Roussy Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Pôle IUCT [CHU Toulouse] Centre Hospitalier Régional Universitaire de Tours CRLCC René Gauducheau Hôpitaux Universitaires de Strasbourg Nanomédecine Régénérative CHU Montpellier = Montpellier University Hospital CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie Centre Hospitalier Régional Universitaire de Besançon CHU Rouen Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] Intergroupe Francophone de Cancérologie Thoracique [Paris] Intergroupe Francophone de Cancérologie Thoracique [Paris] CHU Marseille Institut Curie [Paris] Assistance publique - Hôpitaux de Paris (AP-HP) Institut Curie [Paris] Institut Gustave Roussy
• Publié dans Journal of Clinical Oncology le 01/11/2020

---

Résumé : 9073 Background: TET are associated with autoimmune disorders (AID) in up to 30% of patients (pts). However, there have been wide variations in the reported prevalence of AID in TET pts in small single-center series. RYTHMIC (Réseau tumeurs THYMiques et Cancer) is a French network mandated to systematically discuss every case of TET. We aimed to describe the prevalence of AID in a large French population. Methods: RYTHMIC database, hosted by IFCT (Intergroupe Francophone de Cancérologie Thoracique), prospectively includes all consecutive pts with a diagnosis of TET discussed in French national or regional tumor boards. We analyzed epidemiologic, clinical and pathological characteristics of pts with TET’s related AID. Results: From January 2012 to December 2019, 2909 pts were included in the database. The mean age at diagnosis of TET was 54 and 52% were male. In the overall population, Masaoka Koga stages were well balanced with 12.6% (n = 187) stage I, 8.8% (n = 131) stage IIa, 8.4% (n = 124) stage IIb, 11.1% (n = 164) stage III and 8.5% (n = 125) stage IV. There were 364 (12.5%) events of AID in 302 pts. 62 pts (17%) had more than 1 AID. Among the events, 236 were myasthenia gravis (MG) (64.8%), 19 Hypo-gammaglobulinemia syndrome (5.2%), 15 pure red cell aplasia (4.1%), 18 thyroiditis (4.9%) and 16 systemic erythematous lupus (4.4%). Diagnosis of AID was mostly done at tumor diagnosis (n = 239, 65.7%) but some patient had AID diagnosed before diagnosis (n = 67, 18.4%) or during follow up (n = 32, 8.8%). Among pts presenting AID, B2 was the most common subtype (n = 133, 36.5%). The incidence of AID per subtype was as follow: A (n = 10/81, 12.3%), AB (n = 48/225, 21.3%), B1 (n = 35/130, 26.9%), B2 (n = 133/295, 45.0%), B3 (n = 46/113, 40.7%), thymic carcinoma (n = 16/275, 5.8%). Conclusions: The prevalence of AID in pts with TET was 12.5%, > 40% in B2 and B3 subtypes. Diagnosis of AID can be delayed compared to the diagnosis of TET. Immunotherapy indication should be carefully assessed in pts with TET other than thymic carcinoma.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2020
• Auteurs : I. Poizot‐martinV. Obry‐roguetC. DuvivierC. LionsT. HuleuxC. JacometTristan FerryA. CheretC. AllavenaF. Bani‐sadrR. PalichA. CabiéA. FresardP. PugliesePierre DelobelI. LamauryL. Hustache‐mathieuS. BrégigeonA. MakinsonDominique ReyC Drobacheff-ThiébautA FoltzerKevin BouillerC ChirouzeQ LepillerF BozonO BabreA S BrunelP MuretH LaurichesseO LesensM VidalN MrozekAumeran C.O BaudV CorbinP Letertre-GibertS CasanovaJ ProuteauI FabreE CurlierR OuissaC Herrmann-StorckB TressieresT BonijolyM C ReceveurF BoulardC DanielC ClavelD MerrienP PerréT GuimardO BollangierS LeautezM MorrierL LaineF AderA BeckerF BironA BoibieuxL CotteP MiailhesT PerpointS RouxC Triffault-FillitS DegroodtC BrochierF ValourC ChidiacA MénardA y BelkhirP ColsonC DhiverA MadridM Martin-DegioanniL MeddebM MokhtariA MotteA RaouxI RavauxC TamaletC ToméiH Tissot DupontO Zaegel-FaucherH LarocheM OrticoniM J SoaviP Geneau de LamarlièreE RessiotM J DucassouI JaquetS GalieA GalinierP MartinetM LandonA S RitlengA IvanovaC DebreuxS AbelO CabrasL CuzinK GuitteaudM IlliaquerS Pierre-FrançoisL OseiJ PasquierK RomeE SidaniJ M TurmelC VaracheN AtouiM BistoquetE DelaporteV Le MoingN MeftahC Merle de BoeverB MontesA Montoya FerrerE TuaillonJ ReynesM AndréL BoyerM P BouillonM DelestanC RabaudT MayB HoenC BernaudE BillaudC BironB BonnetS BouchezD BoutoilleC Brunet-CartierC DeschanvresN HallT JovelinP MorineauV ReliquetS SécherM CavellecA SoriaE ParedesV FerréE André-GarnierA RodallecM LefebvreO GrossiO AubryF RaffiS BreaudC CeppiD ChirioE CuaP DellamonicaE DemonchyA de MonteJ DurantC EtienneS FerrandoR GarraffoC MichelangeliV MondainA NaqviN OranI PerbostS PilletC PradierB Prouvost-KellerK RissoV RioP M RogerE RosenthalS SausseI TouitouS Wehrlen-PuglieseG ZouzouL HocquelouxT PrazuckC GubavuA SèveA MakaC BoulardG ThomasC GoujardY QuertainmontE TeicherN LerolleO DeradjiA Barrail-TranR LandmanV JolyJ GhosnC RiouxS LarivenA GervaisF X LescureS MatheronF LouniZ JuliaC Mackoumbou-NkoukaS Le GacC CharpentierD DescampsG PeytavinY YazdanpanahK AmazzoughG BenabdelmoumenP BossiG CessotC CharlierP H ConsignyF DanionA DureaultJ GoeschR GueryB HenryK JidarF LanternierP LoubetO LortholaryC LouisinJ LourencoP ParizeB PilmisF TouamM a ValantinR TubianaR AgherS SeangL SchneiderC BlancC KatlamaJ L BergerY N'GuyenD LambertI KmiecM HentzienA BrunetV BrodardP TattevinM RevestF SoualaM BaldeyrouS Patrat-DelonJ M ChapplainF BenezitM DupontM PoinotA MaillardC PronierF LemaitreC GuennounM Poisson-VanierT JovelinJ P SinteffC ArvieuxE Botelho-NeversA Gagneux-BrunonA FrésardV RonatF LuchtP FischerM PartisaniC CheneauM PriesterM L BatardC Bernard-HenryE de MautortS Fafi-KremerM AlvarezN BiezunskiA DebardCyrille DelpierreP LansalotL LelièvreG Martin-BlondelM PiffautL PorteK SauneF AjanaE AïssiI AlcarazV BacletL BocketA BoucherP ChoisyB Lafon-DesmursA MeybeckM PradierO RobineauN VigetM Valette
• Organismes : Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale Aix Marseille Université Centre d'infectiologie Necker-Pasteur [CHU Necker] Imagine - Institut des maladies génétiques (IHU) Institut Cochin Institut Pasteur [Paris] Aix Marseille Université Centre Hospitalier Gustave Dron [Tourcoing] CHU Clermont-Ferrand Hospices Civils de Lyon Infection à VIH, réservoirs, diversité génétique et résistance aux antirétroviraux (ARV) Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Laboratoire d'Hematologie [CHU Nantes] Hôpital Robert Debré CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Maladies infectieuses et tropicales dans la Caraïbe Centre d'Investigation Clinique Antilles-Guyane Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Universitaire de Nice Centre de Physiopathologie Toulouse Purpan Service Maladies infectieuses et tropicales [CHU Toulouse] CHU Pointe-à-Pitre / Abymes [Guadeloupe] Centre Hospitalier Régional Universitaire de Besançon Aix Marseille Université CHU Montpellier = Montpellier University Hospital Département Maladies Infectieuses et Tropicales [CHRU Montpellier] Hôpitaux Universitaires de Strasbourg Laboratoire Chrono-environnement (UMR 6249) Centre Hospitalier Régional Universitaire de Besançon Laboratoire Chrono-environnement (UMR 6249) Centre Hospitalier Régional Universitaire de Besançon Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) Centre Hospitalier Régional Universitaire de Besançon Service Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand] Service Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand] Laboratoire Géosciences Océan Service Maladies Infectieuses et Tropicales [CHU Clermont-Ferrand] Laboratoire Microorganismes : Génome et Environnement Service Hygiène Hospitalière [CHU Clermont-Ferrand] Université Clermont Auvergne CHU Clermont-Ferrand Dat’AIDS Study Group CCLIN Sud-Est – Centre de Coordination de la Lutte contre les Infections Nosocomiales Sud-Est Service de Maladies Infectieuses et Tropicales Laboratoire Microorganismes : Génome et Environnement Max-Planck-Institut für Kernphysik Service des maladies infectieuses et tropicales Station de Recherche Agronomique de Saint Louis
• Publié dans Journal of the European Academy of Dermatology and Venereology le 27/10/2020

---

Résumé : Background: Although antiretroviral therapy (ART) has reduced the risk of Kaposi sarcoma (KS), KS cases still occur in HIV-infected people. Objective: To describe all KS cases observed between 2010 and 2015 in a country with high ART coverage. Methods: Retrospective study using longitudinal data from 44 642 patients in the French Dat'AIDS multicenter cohort. Patients' characteristics were described at KS diagnosis according to ART exposure and to HIV-plasma viral load (HIV-pVL) (≤50 or >50) copies/mL. Results: Among the 209 KS cases diagnosed during the study period, 33.2% occurred in ART naïve patients, 17.3% in ART-experienced patients and 49.5% in patients on ART, of whom 23% for more than 6 months. Among these patients, 24 (11.5%) had HIV-pVL ≤50 cp/mL, and 16 (66%) were treated with a boosted-PI-based regimen. The distribution of KS localization did not differ by ART status nor by year of diagnosis. Limitations: Data on human herpesvirus 8, treatment modalities for KS and response rate were not collected. Conclusion: Half of KS cases observed in the study period occurred in patients not on ART, reflecting the persistence of late HIV diagnosis. Factors associated with KS in patients on ART with HIV-pVL ≤50 cp/mL remain to be explored.

---

Fichiers liés : jdv.16204.pdf

---

Source